BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26903516)

  • 1. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
    Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
    Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
    Harris CL; Pettigrew DM; Lea SM; Morgan BP
    J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decay acceleration of the complement alternative pathway C3 convertase.
    Hourcade DE; Mitchell LM; Medof ME
    Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
    Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
    J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
    Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
    Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
    J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
    Daha MR; Deelder AM; Van Es LA
    J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
    Hebecker M; Józsi M
    J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus.
    Sharp JA; Cunnion KM
    Mol Immunol; 2011 Jan; 48(4):683-90. PubMed ID: 21163532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Complement Factor B Autoantibodies by ELISA.
    Józsi M; Uzonyi B
    Methods Mol Biol; 2021; 2227():141-145. PubMed ID: 33847939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
    van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
    Front Immunol; 2019; 10():2097. PubMed ID: 31552043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRIT peptide interacts with factor B and interferes with alternative pathway activation.
    Hui KM; Magnadóttir B; Schifferli JA; Inal JM
    Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.